Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098934 | 0.84 | CHRNB2 (0.35) | CNR2HTR3ACHRNB2CHRNA4CHRM4 | |
| SCHEMBL6098297 | 0.83 | AKT1 (0.35) | TAS1R3TAS1R1CNR2CHRNB2CHRNA4 | |
| SCHEMBL6101077 | 0.82 | CHRNB2 (0.35) | CNR2HTR3ACHRNB2CHRNA4CHRM4 | |
| SCHEMBL6100239 | 0.81 | HCRTR1 (0.37) | PDCD1CD274 | |
| SCHEMBL6102034 | 0.81 | AKT1 (0.35) | CNR2CHRNB2CHRNA4CHRM4 | |
| SCHEMBL6098192 | 0.80 | HTR4 (0.43) | TAS1R3TAS1R1CNR2STAT3MALT1 | |
| SCHEMBL6100160 | 0.80 | CNR2 (0.35) | CNR2GRM4CHRNB2CHRNA4 | |
| SCHEMBL6098747 | 0.80 | TAS1R3 (0.36) | TAS1R3TAS1R1CNR2STAT3GRM4 | |
| SCHEMBL6100189 | 0.80 | CHRNB2 (0.34) | HTR4HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6096724 | 0.79 | CTSA (0.44) | TAS1R3TAS1R1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | TAS1R3 4186/4885TAS1R1 3628/4885CNR2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.